Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas
2008 (English)In: European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, E-ISSN 1619-7089, Vol. 35, no 1, 65-71 p.Article in journal (Refereed) Published
The management of adult patients with grade 2 gliomas remains a challenge for the clinical neuro-oncologist. Several clinical prognostic factors appear to be as important as treatment factors in determining outcome. From the European Organisation for Research and Treatment of Cancer (EORTC) trials 22844 and 22845, a prognostic scoring system has been proposed based on the presence of unfavourable prognostic factors. The aim of the present study was to assess the additional prognostic value of (11)C-methionine (MET) measured by positron emission tomography (PET) in the setting of the EORTC prognostic scoring system.
In this retrospective review, 129 patients with supratentorial grade 2 gliomas were subjected to a PET study as part of the pre-treatment tumour investigation. One hundred and three cases were classified as low-risk patients (0-2 unfavourable factors) and 26 cases as high-risk patients (3-5 unfavourable factors) according to the EORTC criteria. MET PET was evaluated as an extra prognostic factor in both groups.
In the high-risk group, patients with high MET uptake had a worse outcome than patients with low MET uptake. A similar trend was found for the low-risk group in patients with oligodendrocytic tumours.
Our findings further strengthen the role of MET PET as an important prognostic tool in the management of this group of patients.
Place, publisher, year, edition, pages
2008. Vol. 35, no 1, 65-71 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-12545DOI: 10.1007/s00259-007-0531-1PubMedID: 17710394OAI: oai:DiVA.org:uu-12545DiVA: diva2:40314